ArticleNature communications2026
An enzyme-specific protein language model for catalytic property prediction.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enzymes drive cellular metabolism, yet predicting catalytic properties from amino acid sequences remains challenging. Existing protein language models (PLMs) provide powerful general-purpose representations but are often inefficient for high-throughput screening and insufficiently adapted to enzyme-specific tasks. Here, we propose EnzGFM, an enzyme-specific PLM based on a Mamba-Transformer hybrid architecture with hierarchical pre-training to capture enzyme-specific patterns. Across enzyme property prediction benchmarks, EnzGFM consistently outperforms Transformer-based PLMs with 2-5-fold acceleration, achieving relative improvements of 16.67% in kinetic parameter prediction, 15.69% in enzyme-reaction mapping, 13.19% in EC number classification, and 20.04% in mutation effect assessment. Building on EnzGFM, we develop EnzGFM-Agent, an enzyme-focused agentic pipeline. Experimental validation further suggests that EnzGFM-Agent can enrich beneficial variants within small candidate pools. Together, these results demonstrate that EnzGFM captures enzyme-specific sequence-function patterns, while EnzGFM-Agent translates these predictions into experimentally actionable candidates and can help reduce wet-lab screening burden for practical enzyme engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.